Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 186

2.
3.
4.
6.

Overactive bladder and men: indications for anticholinergics.

González RR, Te AE.

Curr Urol Rep. 2003 Dec;4(6):429-35. Review.

PMID:
14622494
7.
8.

Safety of anticholinergics in patients with benign prostatic hyperplasia.

Athanasopoulos A, Mitropoulos D, Giannitsas K, Perimenis P.

Expert Opin Drug Saf. 2008 Jul;7(4):473-9. doi: 10.1517/14740338.7.4.473 . Review.

PMID:
18613810
9.

Urinary nerve growth factor levels are increased in patients with bladder outlet obstruction with overactive bladder symptoms and reduced after successful medical treatment.

Liu HT, Kuo HC.

Urology. 2008 Jul;72(1):104-8; discussion 108. doi: 10.1016/j.urology.2008.01.069. Epub 2008 Apr 8.

PMID:
18400272
11.

Pediatric overactive bladder syndrome: pathophysiology and management.

Franco I.

Paediatr Drugs. 2007;9(6):379-90. Review.

PMID:
18052408
12.

Effects of serum PSA on efficacy of tolterodine extended release with or without tamsulosin in men with LUTS, including OAB.

Roehrborn CG, Kaplan SA, Kraus SR, Wang JT, Bavendam T, Guan Z.

Urology. 2008 Nov;72(5):1061-7; discussion 1067. doi: 10.1016/j.urology.2008.06.067. Epub 2008 Sep 25.

PMID:
18817961
13.

Analysis of the prognostic factors for overactive bladder symptoms following surgical treatment in patients with benign prostatic obstruction.

Seki N, Yuki K, Takei M, Yamaguchi A, Naito S.

Neurourol Urodyn. 2009;28(3):197-201. doi: 10.1002/nau.20619.

PMID:
18973143
14.
15.

Benign prostatic obstruction and parkinson's disease--should transurethral resection of the prostate be avoided?

Roth B, Studer UE, Fowler CJ, Kessler TM.

J Urol. 2009 May;181(5):2209-13. doi: 10.1016/j.juro.2009.01.049. Epub 2009 Mar 17.

PMID:
19296974
16.
17.

Anticholinergic therapy for lower urinary tract symptoms associated with benign prostatic hyperplasia.

Gallegos PJ, Frazee LA.

Pharmacotherapy. 2008 Mar;28(3):356-65. doi: 10.1592/phco.28.3.356. Review.

PMID:
18294115
18.

["Pathophysiology and treatment of the overactive bladder"].

Yokoyama O.

Hinyokika Kiyo. 2005 Sep;51(9):599-601. Japanese.

19.

The urologist's view of male overactive bladder: discrepancy between reality and belief in practical setting.

Lee SH, Kim DK, Kim JC, Lee KS, Lee JG, Park CH, Hong SJ, Kim CS, Park JK, Chung BH.

Yonsei Med J. 2010 May;51(3):432-7. doi: 10.3349/ymj.2010.51.3.432. Erratum in: Yonsei Med J. 2010 Jul;51(4):615. Kim, Dae Kyung [added].

20.

Naftopidil and propiverine hydrochloride for treatment of male lower urinary tract symptoms suggestive of benign prostatic hyperplasia and concomitant overactive bladder: a prospective randomized controlled study.

Yokoyama T, Uematsu K, Watanabe T, Sasaki K, Kumon H, Nagai A; Okayama Urological Research Group.

Scand J Urol Nephrol. 2009;43(4):307-14. doi: 10.1080/00365590902836740.

PMID:
19396723

Supplemental Content

Support Center